{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:23:26Z","timestamp":1790688206283,"version":"4.1.0"},"reference-count":39,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OPTH"],"DOI":"10.2147\/opth.s376199","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:20:05Z","timestamp":1661818805000},"page":"2885-2894","source":"Crossref","is-referenced-by-count":13,"title":["Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Michel","family":"Giunta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Pierre","family":"Gauvin Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Steeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"Li","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"ref3","unstructured":"National Eye Institute. Age-related macular degeneration (AMD) data and statistics. Available from: https:\/\/www.nei.nih.gov\/learn-about-eye-health\/resources-for-health-educators\/eye-health-data-and-statistics\/age-related-macular-degeneration-amd-data-and-statistics. Accessed May 3, 2022."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","volume":"129","author":"Klein","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","volume":"114","author":"Klein","year":"2007","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.7.1019","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"ref7","unstructured":"American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern\u00ae; 2019. Available from: https:\/\/www.aao.org\/preferred-practice-pattern\/age-related-macular-degeneration-ppp. Accessed May 3, 2022."},{"key":"ref8","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH therapeutic review: anti-vascular endothelial growth factor drugs for the treatment of retinal conditions \u2014 recommendations report; 2016. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/TR0009_Anti-VEGFs_Recs_Report.pdf. Accessed May 3, 2022."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00417-013-2562-6","volume":"252","author":"Wolf","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"Meht\u00e0","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3341\/kjo.2016.0125","volume":"31","author":"Ozkaya","year":"2017","journal-title":"Korean J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/11206721211001716","volume":"32","author":"Pina Marin","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"Sivaprasad","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2217\/cer-2018-0058","volume":"7","author":"Jaffe","year":"2018","journal-title":"J Comp Eff Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref20","unstructured":"American Society of Retina Specialists. Member update: Novartis-appointed safety review committee reports initial brolucizumab findings; 2020. Available from: https:\/\/www.asrs.org\/clinical\/clinical-updates\/4013\/Member-Update-Novartis-Appointed-Safety-Review-Committee-Reports-Initial-Broluci. Accessed May 3, 2022."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"ref22","unstructured":"Novartis. Post-marketing data in patients with wet AMD. Available from: https:\/\/www.brolucizumab.info\/Post-marketing-data. Accessed May 3, 2022."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20132194. doi:10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/bjophthalmol-2020-318672","volume":"106","author":"Bulirsch","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","volume":"139","author":"Enriquez","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"ref27","unstructured":"Walter SD, Saba NJ Efficacy and durability of brolucizumab in patients being transitioned from prior anti-VEGF therapy. Presented at the ASRS 39th Annual Scientific Meeting; October 8\u201312; 2021; San Antonio (Texas)."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.2147\/OPTH.S328160","volume":"15","author":"Chakraborty","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.3390\/jcm10132758","volume":"10","author":"Bilgic","year":"2021","journal-title":"J Clin Med"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Hussain RM, Neal A, Yannuzzi NA, et al. Real world experience of brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments. Presented at: ASRS 39th Annual Scientific Meeting; October 8\u201312; 2021; San Antonio, Texas.","DOI":"10.1177\/25158414211055964"},{"key":"ref31","first-page":"431","volume":"62","author":"Rave","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref32","unstructured":"Novartis Pharmaceuticals Canada Inc. Lucentis\u00ae (ranibizumab injection) product monograph; 2021."},{"key":"ref33","unstructured":"Bayer Inc. Eylea\u00ae (aflibercept injection) Product Monograph; 2022."},{"key":"ref34","unstructured":"Novartis Pharmaceuticals Canada Inc. Beovu\u00ae (brolucizumab injection) product monograph; 2020."},{"key":"ref35","first-page":"451","volume":"62","author":"Aziz","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref36","first-page":"286","volume":"62","author":"Hamou","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Despreaux\u00a0R,\u00a0Cohen\u00a0SY,\u00a0Semoun\u00a0O, et\u00a0al.\u00a0Short-term\u00a0results of switchback from aflibercept to ranibizumab in neovascular\u00a0age-related macular degeneration in clinical\u00a0practice.\u00a0Graefes Arch Clin Exp Ophthalmol.\u00a02016;254(4):639\u2013644. doi:10.1007\/s00417-015-3084-1","DOI":"10.1007\/s00417-015-3084-1"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Slean\u00a0GR,\u00a0Hemarat\u00a0K,\u00a0Khurana\u00a0RN,\u00a0Stewart\u00a0JM.\u00a0Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in\u00a0age-related macular degeneration: a\u00a0case\u00a0series.\u00a0Int\u00a0J\u00a0Retina Vitreous.\u00a02016;2:2. doi:10.1186\/s40942-016-0028-9","DOI":"10.1186\/s40942-016-0028-9"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2147\/OPTH.S206910","volume":"13","author":"Koike","year":"2019","journal-title":"Clin Ophthalmol"}],"container-title":["Clinical Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=83448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=83448","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:20:17Z","timestamp":1661818817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/early-canadian-real-world-experience-with-brolucizumab-in-anti-vascula-peer-reviewed-fulltext-article-OPTH"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2147\/opth.s376199","relation":{},"ISSN":["1177-5483"],"issn-type":[{"value":"1177-5483","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}